News - 29 Jul `14Clinuvel receives takeover offer from a notorious short seller

New

Clinuvel Pharmaceuticals, drug developer for skin diseases from Melbourne, has received an unsolicited $95 million takeover offer from a controversial biotech company Retrophin, soon after sudden passing of Clinuvel's long time director Jack Wood. 

On behalf of VRF management, we offer our sincere condolences to Jack's wife and family. Jack Wood was a remarkable person with a vision, big heart and brilliant sense of humor. Clinuvel is awaiting clearance from the European drug regulator for the use of its drug Scenesse in the treatment of a rare skin disease Erythropoietic Protoporphyria and potentially, in vitiligo. 

Once a notorious short seller with loud public pressure, Reptophin's CEO Martin Shkreli now aims at drugs for ultra-rare and dangerous conditions. Clinuvel has appointed an advisory firm in the defense against the hostile offer.



      FAQOther Questions

      • PTSD in Vitiligo?

        Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...

      • What's better: laser or phototherapy?

        Both laser treatment and phototherapy are effective options for treating vitiligo, but they each have their own advantages and considerations: Laser Treatment Advantages:- Hig...

      • I have vitiligo: will my children have vitiligo, too?

        If you have vitiligo, you might wonder about the chances of your children developing the condition. While there is a genetic component, vitiligo is not a straightforward heredit...